All In Biotech

Drug Trial Radar · NCT05574894

Effect of GH Supplementation on the Blastocyst Euploid Rate in AMA Patients--A Retrospective Cohort Study

Last checked: Nov 19, 2026Latest source record: Feb 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

692

Actual

Start

Jan 1, 2021

Primary completion

Jun 30, 2022

Study completion Sep 30, 2022

Sponsor

Lead sponsor
ShangHai Ji Ai Genetics & IVF InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 38 years, up to 46 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This retrospective cohort study aims to investigate the effects of recombinant human growth hormone (rh-GH) on the euploid status of preimplantation blastocysts in AMA patients. Infertile patients aged 38-46 years old were recruited for study if they fulfill the inclusion criteria and do not have the exclusion criteria. Treatment group: Women received growth hormone (GH) supplement during antagonist protocol for ovarian stimulation. Control group: Women received antagonist protocol for ovarian stimulation. The primary outcome is the euploidy rate of blastocysts per stimulation cycle and per testing cycle.

Conditions

  • Growth Hormone
  • Advanced Maternal Age
  • PGT-A

Interventions

  • Growth hormoneDrug

    Growth hormone is supplemented during the ovarian stimulation till the day of trigger

  • GnRH antagonistDrug

    GnRH antagonist protocol for ovarian stimulation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of cycles which obtained euploid blastocystsTime frame: 1 month after oocyte retrieval

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai JIAI Genetics and IVF Institute

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.